Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Paul R. Yenson"'
Autor:
Kerry J. Savage, David Scott, Derrick G. Lee, Andrea Lo, Ciara L. Freeman, Anna Hayden, Francois Benard, Joseph M. Connors, Laurie H. Sehn, Diego Villa, Tom Pickles, Alina S. Gerrie, Pedro Farinha, Brian Skinnider, Donald A. Wilson, Petter Tonseth, Graham W. Slack, Paul R. Yenson
Publikováno v:
Blood. 136:2803-2811
Cure rates for primary mediastinal large B-cell lymphoma (PMBCL) have improved with the integration of rituximab. However, the type of primary therapy and role of radiotherapy (RT) remains ill-defined. Herein, we evaluated the outcome of PMBCL primar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22b7ceec8e97af51f9f9a9c0f78b0ae
https://doi.org/10.1182/blood.2019004296
https://doi.org/10.1182/blood.2019004296
Publikováno v:
Canadian Journal of Gastroenterology, Vol 22, Iss 1, Pp 37-40 (2008)
BACKGROUND AND METHODS: Elevated serum ferritin is a common clinical finding. The etiology of hyperferritinemia in the Asia-Pacific population is less clear due to a low prevalence of known HFE mutations such as C282Y and H63D, as well as an increase
Externí odkaz:
https://doaj.org/article/92e85be050244dea959541190df7db10
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis
Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c56d26b2b067acf1922e3952c3a171
https://doi.org/10.1177/1076029617737836
https://doi.org/10.1177/1076029617737836
Autor:
Lauren J. Lee, Paul R. Yenson, Leslie N. Zypchen, Gayatri M. Sreenivasan, Kimberley L.S. Ambler, Kristine J. Roland
Publikováno v:
Transfusion and Apheresis Science. 57:233-235
Solvent detergent-treated plasma (SDP) is a pathogen-inactivated blood plasma, which in comparison to frozen plasma is associated with lower rates of allergic reaction, transfusion-associated lung injury, and viral transmission. SDP has been availabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c51006c954c38e5bd112270a113806
https://doi.org/10.1016/j.transci.2018.02.005
https://doi.org/10.1016/j.transci.2018.02.005
Autor:
Steven R. Foley, Donald M. Arnold, Kathyrn E. Webert, Gail Rock, William F. Clark, Lihua Li, John G. Kelton, David Barth, Paul R. Yenson
Publikováno v:
British Journal of Haematology. 170:208-217
The primary objective of this phase II study was to evaluate the efficacy of rituximab in the management of adult patients with physician-diagnosed presumed thrombotic thrombocytopenic purpura (TTP); relapsed or refractory. We conducted a multicentre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05de790190b48b47f9d218ff0882bc9
https://doi.org/10.1111/bjh.13408
https://doi.org/10.1111/bjh.13408
Autor:
Kevin H.M. Kuo, Stephen Couban, Paul R. Yenson, Veronique Naessens, David Barth, Bruce Ritchie, Richard Ward
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 55(1)
We outline a case whereby RBCX was successfully provided over disparate geographical areas and time zones in Canada and overcame the logistical challenges of coordinating care across four different health care systems with the application of modern t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c11ac515b0de5f851638584e0a17e419
https://pubmed.ncbi.nlm.nih.gov/27179925
https://pubmed.ncbi.nlm.nih.gov/27179925
Autor:
Victor S. Blanchette, Paul R. Yenson, Colleen Notley, Manuel Carcao, Margaret L. Rand, David Lillicrap, J. D. Robertson, Paula D. James
Publikováno v:
Journal of Thrombosis and Haemostasis. 9:1752-1760
Summary. Background: Recent phenotype–genotype studies have provided valuable insights into the pathophysiology of type 1 von Willebrand disease (VWD); however, no study has examined an exclusively pediatric cohort. Objectives: To describe phenotyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb5842a6891e73553e1b78bad4c8e8c1
https://doi.org/10.1111/j.1538-7836.2011.04423.x
https://doi.org/10.1111/j.1538-7836.2011.04423.x
Autor:
Raewyn Broady, Cynthia L. Toze, Alina S. Gerrie, David Sanford, Yasser Abou Mourad, Gayatri M. Sreenivasan, Kevin W. Song, Heather J. Sutherland, Laurie H. Sehn, Parv Chapani, Maryse M. Power, Stephen H. Nantel, Diego Villa, Paul R. Yenson, Hatem Alahwal
Publikováno v:
Blood. 132:4556-4556
Introduction In 2013, bendamustine/rituximab (BR) replaced RCHOP as standard first line treatment for both transplant eligible and ineligible MCL patients (pts) in BC. Retrospective cohort studies report that bendamustine has no adverse effect on per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24ccfe0df6fe96542dd5abb7d3a98a91
https://doi.org/10.1182/blood-2018-99-114371
https://doi.org/10.1182/blood-2018-99-114371
Publikováno v:
Canadian Journal of Gastroenterology, Vol 22, Iss 1, Pp 37-40 (2008)
BACKGROUND AND METHODS: Elevated serum ferritin is a common clinical finding. The etiology of hyperferritinemia in the Asia-Pacific population is less clear due to a low prevalence of knownHFEmutations such asC282YandH63D, as well as an increased pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183bded49d54bbf43c234147e5c78d50
https://doaj.org/article/92e85be050244dea959541190df7db10
https://doaj.org/article/92e85be050244dea959541190df7db10
Autor:
Mark Baerlocher, Erica A. Peterson, Chad Kim Sing, Michael Delorme, Jason Wong, Gavin Greenfield, James Dooner, Randolph Guzman, Otto Moodley, Joel Gagnon, Leslie Zypchen, David M. Liu, Paul R. Yenson
Publikováno v:
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 187(17)
Venous thromboembolism, presenting as deep vein thrombosis (DVT) or pulmonary embolism, affects over 35 000 Canadians each year.[1][1] It is associated with substantial morbidity, mortality and burden on the Canadian health care system, with one-mont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69c25aa5827d156da862635bcd49a0fc
https://pubmed.ncbi.nlm.nih.gov/26416989
https://pubmed.ncbi.nlm.nih.gov/26416989